Literature DB >> 9193847

Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients.

H Hohage1, M Arlt, D Brückner, K H Dietl, W Zidek, C Spieker.   

Abstract

After allogenic transplantations a dramatic increase in the development of arteriosclerotic plaques can be observed, which might be due to metabolic alterations, influenced by changes of the transplant organ or immunosuppression. In this study the effects of FK 506 in kidney transplant patients on cardiovascular risk factors were compared to cyclosporin A (CsA) immunosuppression. Both groups showed no statistical differences in number, kidney function, age, body weight, sex distribution, steroid dosage and follow-up time after transplantation. Total cholesterol was similar in FK 506-treated patients (231 +/- 22 vs. 278 +/- 52 mg/dl) as compared with patients with CsA immunosuppression. Furthermore, there were no differences in triglycerides (220 +/- 72 vs. 210 +/- 67 mg/dl), HDL-cholesterol (67 +/- 14 vs. 52 +/- 18 mg/dl) and fasting glucose (112 +/- 36 vs. 116 +/- 17 mg/dl). However, the concentration of LDL-cholesterol (114 +/- 21 vs. 167 +/- 37 mg/dl), the independent risk factor Lp(a) (11 +/- 9 vs. 27 +/- 8 mg/dl) and fibrinogen (216 +/- 71 vs. 297 +/- 47) was lower in FK 506-treated patients. Our results indicate that FK 506 immunosuppression offers some advantages in cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193847

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.

Authors:  Keith K Lau; Daniel J Tancredi; Richard V Perez; Lavjay Butani
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

3.  Higher tacrolimus blood concentration is related to hyperlipidemia in living donor liver transplantation recipients.

Authors:  Hong-Yu Li; Bo Li; Yong-Gang Wei; Lv-Nan Yan; Tian-Fu Wen; Ji-Chun Zhao; Ming-Qing Xu; Wen-Tao Wang; Yu-Kui Ma; Jia-Yin Yang
Journal:  Dig Dis Sci       Date:  2011-07-09       Impact factor: 3.199

Review 4.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 5.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 6.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Effects of renal replacement therapy on plasma lipoprotein(a) levels.

Authors:  Sylvia Rosas; Marshall Joffe; Megan Wolfe; Kenneth Brayman; Daniel J Rader
Journal:  Am J Nephrol       Date:  2007-12-05       Impact factor: 3.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.